Anti-doping comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-10-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Also called GW501516 and endurobol. |
| Chemical formula | C21H18F3NO3S2 | Molecular weight about 453.5 g/mol. |
| Appearance | White to off-white solid | Form depends on synthesis and purity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, protected from light | Common for research chemicals. |
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
In April 1995, Austin took part in a tournament for the vacant United States Championship, defeating Jim Duggan via countout in the first round but losing to Randy Savage in the quarter-final. He wrestled what would be his final match with WCW on May 21, 1995, defeating Eddie Jackie in a bout that aired on WCW Main Event. In late May and June 1995, Austin again appeared with New Japan Pro-Wrestling as part of its "Fighting Spirit Legend" series, primarily teaming with Arn Anderson and Ron Simmons. At the "Super Power Group Declaration VI" event in the Nippon Budokan in Tokyo, Austin, Anderson, and Mike Enos lost to J-J-Jacks (Akira Nogami and Takayuki Iizuka) and Junji Hirata in a six-man tag team match. During the NJPW tour, Austin suffered a torn triceps. While rehabilitating, Austin was fired by WCW President Eric Bischoff on September 15, 1995. Bischoff did not see Austin as a marketable wrestler, and additionally thought Austin was hard to work with.
Fishbone is the recording debut of alternative group Fishbone. This six-song EP was released in 1985 and captures the band at the height of their early funk/ska era. The track "Party at Ground Zero" remains one of the band's most popular tracks. The track "V.T.T.L.O.T.F.D.G.F." stands for "Voyage to the Land of the Freeze-Dried Godzilla Farts", as confirmed on the band's website, and imagines a government attempt to convince the public that Hiroshima was actually caused by Godzilla farting.
MS1 is a positive allosteric modulator (PAM) of the μ-opioid receptor (MOR). It was developed from structural modification of the earlier MOR PAM BMS‐986122. The drug has been found to augment the affinity of the MOR agonist levomethadone ((R)-methadone) for the MOR by 7-fold in vitro and to potentiate activation of the MOR by levomethadone by 4-fold in a G protein assay. However, MS1 displays strong probe dependence, and while it potentiates the MOR agonists levomethadone and morphine, it had no effect on the affinity or potency of the MOR agonists DAMGO or endomorphin-1. MS1 shows a preference for β-arrestin recruitment over G protein activation with endomorphin-1 exposure. The drug's actions are reportedly similar to those of BMS-986122, though its unclear if their mechanisms of action are the same. MS1 shows potentiated analgesic effects with opioids in animals. It also did not worsen opioid withdrawal symptoms, respiratory depression, or analgesic tolerance. MS1 and other atypical MOR activators are of potential interest in the development of novel opioid analgesics with reduced adverse effects and misuse potential. MS1 has notably been found to penetrate the blood–brain barrier in animals. The potential of the related MOR PAMs BMS-986121 and BMS-986122 as pharmaceutical drugs has been restricted owing to their complex chemical synthesis. MS1 has a much simpler synthesis in comparison and hence has been regarded as having overcome this limitation. MS1 was first described in the scientific literature by 2015.
These properties of the two sub-units, allow the opioid receptor's G protein to permanently interact with the membrane via lipid anchors. When an agonistic ligand binds to the opioid receptor, a conformational change occurs, and the GDP molecule is released from the Gα sub-unit. This mechanism is complex, and is a major stage of the signal transduction pathway. When the GDP molecule is attached, the Gα sub-unit is in its inactive state, and the nucleotide-binding pocket is closed off inside the protein complex. However, upon ligand binding, the receptor switches to an active conformation, and this is driven by intermolecular rearrangement between the trans-membrane helices. The receptor activation releases an 'ionic lock' which holds together the cytoplasmic sides of transmembrane helices three and six, causing them to rotate. This conformational change exposes the intracellular receptor domains at the cytosolic side, which further leads to the activation of the G protein. When the GDP molecule dissociates from the Gα sub-unit, a GTP molecule binds to the free nucleotide-binding pocket, and the G protein becomes active. A Gα(GTP) complex is formed, which has a weaker affinity for the Gβγ sub-unit than the Gα(GDP) complex, causing the Gα sub-unit to separate from the Gβγ sub-unit, forming two sections of the G protein. The sub-units are now free to interact with effector proteins; however, they are still attached to the plasma membrane by lipid anchors.
== History == For decades, the public viewed the house as the "Birthplace of Insulin," and many individuals expressed their desire to have it turned into a shrine or monument to honour the Canadian hero. It was first internationally referred to with the title "Birthplace of Insulin," in 1923, by the Detroit Free Press. After 47 years, the house received official recognition in 1970, in the form of a plaque for the house, awarded by the London Public Library Board. In 1981, the London & District Branch of the Canadian Diabetes Association purchased the house, and began to use it as an office; they hoped to eventually restore the house, and turn it into a museum. Through various grants and fundraising efforts, by 1984, the museum was operational.
Sources: en.wikipedia.org
The legislative council was a permanent body, with a third of its members retiring every three years and having the power to decide on bills passed by the assembly. In 1939, the Governor-General of India declared India's entry into World War II without consulting the Imperial Legislative Council. The Indian National Congress protested by asking all its elected representatives to resign from governments. It was reconstituted after new provincial elections were conducted in 1946. The governance structure also evolved from a modest secretariat with a single secretary for the public department in 1670 to six departments overseen by a chief secretary by 1920.
The meta-analysis also noted that the mechanisms of acupuncture "are clinically relevant, but that an important part of these total effects is not due to issues considered to be crucial by most acupuncturists, such as the correct location of points and depth of needling" and that acupuncture may be "associated with more potent placebo or context effects" than other treatments. Commenting on these findings, both Edzard Ernst and David Colquhoun said the results were of negligible clinical significance. A 2011 overview of Cochrane reviews found evidence that suggests acupuncture is effective for some but not all kinds of pain. A 2010 systematic review found that there is evidence "that acupuncture provides a short-term clinically relevant effect when compared with a waiting list control or when acupuncture is added to another intervention" in the treatment of chronic low back pain. Two review articles discussing the effectiveness of acupuncture, from 2008 and 2009, have concluded that there is not enough evidence to conclude that it is effective beyond the placebo effect. Acupuncture is generally safe when administered using Clean Needle Technique (CNT). Although serious adverse effects are rare, acupuncture is not without risk. Severe adverse effects, including very rarely death (five case reports), have been reported.
== External links == Target+Peptide at the U.S. National Library of Medicine Medical Subject Headings (MeSH) SPdb (Signal Peptide DataBase) Archived 2016-01-22 at the Wayback Machine Prediction methods: SignalP — predicts the presence and location of signal peptide cleavage sites in amino acid sequences from all domains of organisms. PHOBIUS - combined transmembrane topology and signal peptide predictor
Mahathir established the Kuala Lumpur Initiative to Criminalise War Forum in an effort to end war globally, as well as the Kuala Lumpur War Crimes Commission to investigate the activities of the United States, Israel and its allies in Iraq, Lebanon and the Palestinian territories. In March 2015, Mahathir attended a conference where he stated his belief in a "New World Order", where an elite would attempt rule the planet in a single world government, and exterminate billions of humans.
== History == The detection of nitrates and nitrites for GSR has been around since the early 1900s. The first recorded use of paraffin wax as a lifting medium was done by Dr. Iturrioz in 1914 and was popularized in 1933 by Teodoro Gonzalez of the Mexico City Police Laboratory. The aptly named paraffin test is also referred to as the diphenylamine test, dermal nitrate test and the Gonzalez test. This test consisted of coating a suspect's hands with paraffin wax, allowing it to solidify and peeling it away before adding a diphenylamine/sulfuric acid reagent. The presence of dark blue spots is said to indicate a positive result. This is no longer used in casework due to the high number of false positives caused by the commonality of nitrates and nitrites in a variety of mundane products such as fertilisers. In 1971 John Boehm presented some micrographs of gunshot residue particles found during the examination of bullet entrance holes using a scanning electron microscope. If the scanning electron microscope is equipped with an energy-dispersive X-ray spectroscopy detector, the chemical elements present in such particles, mainly lead, antimony and barium, can be identified. In 1979 Wolten et al. proposed a classification of gunshot residue based on composition, morphology, and size. Four compositions were considered characteristic:
Sources: en.wikipedia.org
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.
It activates PPARδ, a nuclear receptor that influences gene expression related to lipid and energy metabolism. Animal studies show changes in endurance and lipid levels. Human effects and risks are not well established.
No, cardarine is not a steroid. It belongs to a different chemical class, the PPARδ agonists. It is also not a selective androgen receptor modulator.
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.